<DOC>
	<DOCNO>NCT00037869</DOCNO>
	<brief_summary>The goal clinical research study learn I-131 Metaiodobenzylguanidine ( MIBG ) shrink slow growth tumor ( ) patient metastatic neuroendocrine tumor . The safety treatment also study .</brief_summary>
	<brief_title>High Dose I-131 Metaiodobenzylguanidine ( MIBG ) Metastatic Neuroendocrine Tumors</brief_title>
	<detailed_description>MIBG use visualize group specific cell body . It know deliver radioactive iodine tumor ( cancer ) cell selectively result destruction . Before treatment start , patient evaluate tracer scan , use either I-131 MIBG I-123 MIBG locate tumor site ( ) . If MIBG accumulation find within tumor site , patient able continue study . Patients also CT scan urine blood test . Women able child pregnancy test . If tumor site find patient fully eligible , receive therapeutic ( treatment ) dose I-131 MIBG vein 120 minute . Some patient may receive low dose MIBG . Patients require hospitalization treatment remain hospitalized 3-6 day .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Age : 2 year age old Sex : male female ; female patient child bear potential must negative serum HCG pregnancy test within 72 hour prior treatment ; Diagnostic criterion Patients must meet following : 1 . Histologically documented neuroendocrine tumor . 2 . Labeled MIBG concentration tumor site ( ) diagnostic scan . 3. good excellent performance status . A patient write voluntary informed consent obtain prior study participation . Patients prior chemotherapy , long hematological parameter meet specification . Please refer Appendix D Drugs Other Interactions list medication patient need cease 2 week prior therapy . Patient check primary physician therapy resume medication . Patients treatment refractory relapse advanced disease amendable significant response ( &gt; 25 % available chemotherapy ) metastatic disease amenable standard therapy . Patients inadequate hematopoietic bone marrow function : ANC &lt; 1000 cells/mm3 , platelet &lt; 75k cells/mm3 hemoglobin &lt; 10g/dL . Patients impaired renal function : creatinine &gt; 1.5mg/dL . Patients impaired hepatic function : AST ALT &gt; 3.0 X upper limit normal total bilirubin &gt; 2.0 mg/dL . Patients dementia alter mental status would prohibit give understand informed consent time study entry . Female patient breastfeed . Children le 2 year age . Patients previous total body irradiation .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Metastatic neuroendocrine tumor</keyword>
</DOC>